Literature DB >> 16893995

Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.

Francis Michon1, Catherine Uitz, Arun Sarkar, Anello J D'Ambra, Maryline Laude-Sharp, Samuel Moore, Peter C Fusco.   

Abstract

Recent efforts toward developing vaccines against group B streptococci (GBS) have focused on increasing the immunogenicity of GBS polysaccharides by conjugation to carrier proteins. However, partial depolymerization of GBS polysaccharides for the production of vaccines is a difficult task because of their acid-labile, antigenically critical sialic acids. Here we report a method for the partial depolymerization of type II and III polysaccharides by mild deaminative cleavage to antigenic fragments with reducing-terminal 2,5-anhydro-d-mannose residues. Through the free aldehydes of their newly formed end groups, the fragments were conjugated to tetanus toxoid by reductive amination. The resulting conjugates stimulated the production in animals of high-titer type II- and III-specific antibodies which induced opsonophagocytic killing of type II and III strains of group B streptococci. For the type II conjugates, immunogenicity increased as oligosaccharide size decreased, whereas for type III conjugates, the size of the oligosaccharides did not significantly influence immunogenicity. When oligosaccharides of defined size were conjugated through sialic acid residues, the resulting cross-linkages were shown to affect immunogenicity. When oligosaccharides were conjugated through terminal aldehyde groups generated by deamination, modification of the exocyclic chain of sialic acid did not influence immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893995      PMCID: PMC1539122          DOI: 10.1128/CVI.00122-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  26 in total

1.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method.

Authors:  L SVENNERHOLM
Journal:  Biochim Biophys Acta       Date:  1957-06

2.  Bactericidal activity elicited by the beta C protein of group B streptococci contrasted with capsular polysaccharides.

Authors:  P C Fusco; J W Perry; S M Liang; M S Blake; F Michon; J Y Tai
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

3.  Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

Authors:  C A Laferriere; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

Authors:  M R Wessels; L C Paoletti; H K Guttormsen; F Michon; A J D'Ambra; D L Kasper
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

5.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.

Authors:  M R Wessels; L C Paoletti; D L Kasper; J L DiFabio; F Michon; K Holme; H J Jennings
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

6.  NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives.

Authors:  J R Brisson; S Uhrinova; R J Woods; M van der Zwan; H C Jarrell; L C Paoletti; D L Kasper; H J Jennings
Journal:  Biochemistry       Date:  1997-03-18       Impact factor: 3.162

Review 7.  Group B streptococcal vaccines.

Authors:  C J Baker; D L Kasper
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

8.  Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide.

Authors:  H J Jennings; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1981-08-04       Impact factor: 3.162

9.  Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.

Authors:  P Anderson; M E Pichichero; R A Insel
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

10.  Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein.

Authors:  F Michon; P C Fusco; C A Minetti; M Laude-Sharp; C Uitz; C H Huang; A J D'Ambra; S Moore; D P Remeta; I Heron; M S Blake
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

View more
  9 in total

1.  Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine.

Authors:  Samuel Moore; Esmé K Farley; Peter C Fusco; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

2.  Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide.

Authors:  Filippo Carboni; Roberto Adamo; Monica Fabbrini; Riccardo De Ricco; Vittorio Cattaneo; Barbara Brogioni; Daniele Veggi; Vittoria Pinto; Irene Passalacqua; Davide Oldrini; Rino Rappuoli; Enrico Malito; Immaculada Y Ros Margarit; Francesco Berti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

3.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

4.  Evaluation of the Immunomodulatory Properties of Streptococcus suis and Group B Streptococcus Capsular Polysaccharides on the Humoral Response.

Authors:  Cynthia Calzas; Morgan Taillardet; Insaf Salem Fourati; David Roy; Marcelo Gottschalk; Hugo Soudeyns; Thierry Defrance; Mariela Segura
Journal:  Pathogens       Date:  2017-04-20

5.  Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development.

Authors:  Fikri Avci; Francesco Berti; Peter Dull; John Hennessey; Viliam Pavliak; A Krishna Prasad; Willie Vann; Michael Wacker; Olivier Marcq
Journal:  mSphere       Date:  2019-09-25       Impact factor: 4.389

Review 6.  Bacterial and Host Determinants of Group B Streptococcal Vaginal Colonization and Ascending Infection in Pregnancy.

Authors:  Alyssa Brokaw; Anna Furuta; Matthew Dacanay; Lakshmi Rajagopal; Kristina M Adams Waldorf
Journal:  Front Cell Infect Microbiol       Date:  2021-09-03       Impact factor: 5.293

Review 7.  Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines.

Authors:  Chakkumkal Anish; Michel Beurret; Jan Poolman
Journal:  NPJ Vaccines       Date:  2021-12-10       Impact factor: 7.344

Review 8.  Impact and Control of Sugar Size in Glycoconjugate Vaccines.

Authors:  Giuseppe Stefanetti; Calman Alexander MacLennan; Francesca Micoli
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

Review 9.  Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.

Authors:  Peter Klein Klouwenberg; Louis Bont
Journal:  Clin Dev Immunol       Date:  2008
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.